Victoria Minister for Technology Gordon Rich-Phillips
GSK Injects $60 Million And 58 Jobs At Boronia Site
Victor P Taffa
Minister for Technology Gordon Rich-Phillips today announced that one of the world’s leading pharmaceutical companies, GlaxoSmithKline Pty Ltd (GSK), will invest $60 Million to expand its Boronia site, creating 58 new highly-skilled jobs by 2017.
Mr. Rich-Phillips said the Victorian Coalition Government was supporting GSK to expand its manufacturing and new drug development activities in Victoria.
“This investment by GSK is of major significance to Victoria’s pharmaceutical industry, and the Victorian economy.” Mr. Rich-Phillips said.
GSK is a significant contributor to the Victorian economy in terms of employment, exports, manufacturing and local R&D investment, expending on average more than $30 Million a year on R&D in Victoria and consistently exporting more than $300 Million p.a. in pharmaceutical products from the state.
GSK’s manufacturing plant in Boronia is the company’s largest site globally for the production of sterile and non-sterile liquid products that utilise state-of-the-art ‘blow-fill-seal’ (BFS) technology.
Mr. Rich-Phillips said the $60 Million investment would allow GSK to potentially double its current BFS manufacturing capacity by installing new BFS production technology, as well as supporting the creation of a pilot scale industrialisation facility for the development of new powder and sterile liquid pharmaceutical products.
“The industrialisation facility will also support the continuation of GSK’s successful R&D collaboration with the Monash Institute of Pharmaceutical Sciences in developing next generation pharmaceutical products.” Mr. Rich-Phillips said.
“GSK also plans to make this new facility accessible for local companies for contract manufacturing, further supporting skills development and technology transfer opportunities for Victorian researchers and companies.”
“The Victorian Coalition Government is investing in the life sciences sector to ensure that the right conditions exist in Victoria to support the growth of life sciences companies, such as GSK.”
“We recently released Victoria’s Technology Plan for the Future Biotechnology a $55 Million plan to promote biotechnology-enabled innovation and support the growth of Victoria’s life sciences sector.”
“With a focus on capability development, the plan provides support to develop the necessary talent pool in Victoria, capitalise on our world-class R&D base, and pursue international trade and investment opportunities.” Mr. Rich-Phillips said.
Minister for Manufacturing, Exports and Trade Richard Dalla-Riva said this announcement built on the release of the Coalition Government’s manufacturing strategy that would strengthen Victoria’s manufacturing industry to secure jobs and grow business investment.
“A more competitive manufacturing industry will strengthen Victoria’s manufacturing industry to create more opportunities for businesses to grow and become more productive and competitive in a tough global market.” Mr. Dalla-Riva said.
“GSK’s $60 Million investment and commitment to creating 58 new jobs in product development and manufacturing in Victoria is a major boost for pharmaceutical manufacturing in Victoria.”
GSK Boronia Site Director Troy Webb said this was a unique opportunity to put Victoria and Australia on the map when it comes to scientific innovation, particularly around ophthalmic, biological and consumer healthcare products.
“With the Victorian Government as a key supporter, this investment will build a sustainable manufacturing capability within the local community while driving manufacturing technology.” Mr. Webb said.